Forma Therapeutics Announces the Appointment of Acclaimed Global Leader in Sickle Cell Disease Ifeyinwa Osunkwo, MD, MPH, as Senior Vice President, Director of Patients


WATERTOWN, Mass., November 30, 2021– (BUSINESS WIRE) – Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the appointment of Ifeyinwa (Ify) Osunkwo , MD, MPH, for the leadership team as Senior Director of Patients and Senior Vice President of the Company. In this role, Dr Osunkwo will be responsible for realizing Forma’s vision of transforming patients’ lives by improving access and care through partnerships with patients and community actors around the world. She will join Forma in the first quarter of 2022.

“This appointment of a Chief Patient Officer boldly represents our commitment to advancing both patient access and care as well as potential innovative treatments. We are honored that Ify has chosen to join Forma at this time. critical of the growth of our organization as a trusted patient – a company centered, ”said Frank Lee, President and CEO of Forma.“ Ify understands what it’s like to directly care for people with sickle cell disease because she devoted her professional life to it. His role is crucial to our mission to transform patients’ lives. We have no doubts about the impact it will have on a global level. “

Dr Osunkwo is an internationally recognized expert in the research, treatment and care of sickle cell disease (SCD), the transition from pediatric to adult care, and the management of chronic pain. She is passionate about health equity and has focused her research on identifying the comparative effectiveness of interventions to eliminate health disparities in black and brown populations. She has over 25 years of experience in clinical management, population health using the chronic disease management model, and health literacy. She is an accomplished clinical educator, able to train clinical and non-clinical audiences and is also a visionary leader in the development and implementation of pragmatic programs using quality improvement.

“I am delighted to be able to continue to build meaningful partnerships with patients and community stakeholders in my role at Forma,” said Dr. Osunkwo. “Improving the overall experience of patients with sickle cell disease has been my professional passion; it’s an opportunity to really focus on delivering new treatments to patients around the world. My vision is that everyone living with sickle cell disease has access to basic care and disease management. My hope is to amplify the impact I can have on the community.

Dr Osunkwo is the Founder and Director of the Sickle Cell Disease Enterprise at the Levine Cancer Institute and Professor of Medicine and Pediatrics at Atrium Health – a vertically integrated healthcare system serving over 1,400 adults and 400+ children with sickle cell disease in NC / SC / GEORGIA. Previously, she was Medical Director of the Comprehensive Sickle Cell Disease Program at Children’s Healthcare Atlanta @ Egleston and Assistant Professor of Pediatrics at Emory University. She led the Teen Scene Transition Program which provided care coordination and education to facilitate the smooth transition of young adults from pediatrics to adult care. Dr Osunkwo received a medical degree from the College of Medical and Dental Sciences at the University of Nigeria and an MPH from the School of Hygiene and Public Health at Johns Hopkins University. She received her residency training in pediatrics at the University of Medicine and Dentistry of New Jersey and completed her fellowship in pediatric hematology, oncology, and bone marrow transplantation at Columbia University College of Physicians and Surgeons. Dr. Osunkwo is Board Certified in Pediatric Hematologic Oncology and has led a strong research company raising over $ 15 million in research funding and has been a Principal Investigator in numerous clinical trials during her career.

About Forma Therapeutics

Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapies to transform the lives of patients with rare hematological diseases and cancers. Our R&D engine combines in-depth knowledge of biology, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on high unmet need indications. Our work has generated a large portfolio of proprietary programs with the potential to bring profound benefits to patients. For more information, please visit or follow us on Twitter @FORMAInc and LinkedIn.

Forward-looking statements

This press release may contain forward-looking statements and information within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may”, “will”, “could”, “should”, “should”, “expect”, “intend”, “plan”, “anticipate”, “believe” “,” Believes “,” predicted “,” projects “,” research “,” strives “,” possible “,” pursue “,” ‘forward-looking statements contain these identifying words. The express or implied forward-looking statements included in this press release are predictions only and are subject to a number of risks, uncertainties and assumptions, including, without limitation, the risks set forth under the heading “Risk Factors” in Forma’s quarterly report on Form 10 -Q for the quarter ended September 30, 2021, as well as other risks detailed in our subsequent filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances mentioned in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely on forward-looking statements as predictions of future events. Although Forma believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or will occur. In addition, except as required by law, neither Forma nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release represents the views of Forma only as of the date on which it was made. Forma assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

See the source version on


Adam Silverstein, +1 917-697-9313
Porter Novelli
[email protected]

Mario Corso, +1 781-366-5726
Forma Therapeutics
[email protected]


Comments are closed.